BWAY Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Brainsway Ltd (BWAY) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's strong financial growth, positive analyst ratings, and strategic investments in mental health technology indicate solid long-term potential. Despite recent price declines, the technical indicators and support levels suggest a reasonable entry point for long-term investors.
The MACD is negatively expanding (-0.0777), indicating bearish momentum. RSI is neutral at 42.211, not signaling overbought or oversold conditions. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200), suggesting an upward trend in the longer term. The stock is near its first support level (S1: 22.836), which could act as a price floor.
Analysts have raised price targets to $30, citing FDA-approved protocols and strategic partnerships.
The company announced a minority investment in BrainStim Health, strengthening its position in mental health technology.
Revenue, net income, and EPS have shown significant YoY growth in Q3 2025.
Recent price decline (-4.27% regular market change) may indicate short-term bearish sentiment.
No significant hedge fund or insider trading trends, suggesting limited institutional activity.
In Q3 2025, revenue increased by 28.66% YoY to $13.51M. Net income rose by 136.56% YoY to $1.566M, and EPS doubled to 0.04. Gross margin improved to 75.19%, up 2.27% YoY, reflecting strong operational efficiency.
Analysts are bullish, with recent upgrades in price targets to $30 from $24 and $23. Positive sentiment is driven by FDA-approved protocols, strategic partnerships, and a promising outlook for mental health interventions.
